Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05222802 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
A Phase 1 study of Glioblastoma Multiforme, sponsored by Katmai Pharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 8
- Study locations
NCT05222802 is a Phase 1 study of Glioblastoma Multiforme that is active but no longer recruiting, run by Katmai Pharmaceuticals. The registered enrollment target is 52 participants, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (46% lower). The trial reports 8 study locations across 8 states.
The verdict
NCT05222802, a Phase 1 study of Glioblastoma Multiforme, is active but no longer recruiting, sponsored by Katmai Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 8
- Study locations
Study Summary
* To evaluate the safety and tolerability of escalating doses of ERAS-801 in study participants with recurrent glioblastoma multiforme (GBM). * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-801. * To evaluate the antitumor activity of ERAS-801. * To evaluate the PK profile of ERAS-801.
Conditions Studied
Interventions
- DRUG ERAS-801
Study Locations (8)
California
- University of California, Los Angeles - Los Angeles
Florida
- Miami Cancer Institute-Baptist Heath South Florida - Miami
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- Henry Ford Health System - Detroit
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Cleveland Clinic Foundation - Cleveland
Tennessee
- Sarah Cannon Research Institute (Tennessee Oncology) - Nashville
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2022-02-25 |
| Est. Completion | 2025-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05222802
The ClinicalTrials.gov registry entry for NCT05222802 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (46% lower). The listed sponsor is Katmai Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention - of which ERAS-801 is the first listed.
NCT05222802 reports 8 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05222802 about?
NCT05222802 is a clinical study titled "A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)". * To evaluate the safety and tolerability of escalating doses of ERAS-801 in study participants with recurrent glioblastoma multiforme (GBM). * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-801. * To evaluate the antitumor activity of ERAS-801. * To evaluate the ...
What is the current status of trial NCT05222802?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2022-02-25. Estimated completion is 2025-09-30.
What conditions does trial NCT05222802 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme.
What interventions are being tested in trial NCT05222802?
The interventions under investigation include: ERAS-801 (DRUG).
Who is sponsoring clinical trial NCT05222802?
This trial is sponsored by Katmai Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05222802 being conducted?
This trial has 8 study locations across California, Florida, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
RECRUITING · Phase 1
-
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
RECRUITING · Phase 1
-
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RECRUITING · Phase 1
-
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.